If you are having trouble viewing this email, you may see it online.
Dear Colleague,
Real World Evidence (RWE) is gaining increasing importance not just from a payer perspective but also from a regulatory perspective. The recent release of the FDA's new strategic framework to advance the use of RWE to support development of drugs and biologics reinforces the fact that there is an ever growing interest to not only generate real world evidence but also demonstrate value to relevant stakeholders involved in the patient access decision making process. 

New age healthcare apps and digital therapeutics are also gaining a lot of traction, and real world evidence is critical in measuring the impact of these interventions on health outcomes.

Register here to attend our free webinar on March 5th 2019 from 11-12 PM EST where leading industry SMEs and speakers will provide their unique perspectives on:
  • Generating and harnessing real world evidence in the era of big data
  • Immuno-oncology, survival modeling and nice assessment
  • How to collect RWE to show an app increases patient engagement & improves outcomes


Madhur Garg

Director, Real World Evidence
Sciformix, A Covance Company

Kelly Zou
Vice President, Medical Analytics & Insights, R&D and Medical, Upjohn Division
Pfizer Inc.

Murvin Jootun
Covance Market Access & Phase IV Solutions

Swatee Surve

Founder and CEO



This email was sent on behalf of Sciformix by HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here, or send your request in writing to the address above.
Read more about our privacy policy here. You may also request a copy in writing using the address above.

To ensure you continue to receive emails from HealthEconomics.Com, please click here.